Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPIT: Trough Level Optimized Infliximab in Pediatric Crohn's Disease
NCT02522169Unknown
- Sponsor
- Klinikum Westbrandenburg
- Start
- Sep 2015
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
01
Overview
Randomised, single-blind trial of infliximab in Crohn's disease, sponsored by Klinikum Westbrandenburg. Primary endpoint: Disease Remission at 12 months. Status: unknown.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02522169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02522169.